Ferring Pharmaceuticals AS
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$12.6M
Doctors Paid
96
Transactions
2,226
2024 Total
$1.8M
Payment Breakdown by Category
Research$12.0M (95.2%)
Consulting$425,938 (3.4%)
Travel$148,690 (1.2%)
Food & Beverage$14,349 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $12.0M | 1,779 | 95.2% |
| Consulting Fee | $425,938 | 81 | 3.4% |
| Travel and Lodging | $148,690 | 172 | 1.2% |
| Food and Beverage | $14,349 | 191 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,947 | 3 | 0.1% |
Payments by Type
Research
$12.0M
1,779 transactions
General
$596,923
447 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| An open-label, randomised, 2-way crossover, single dose, pharmacokinetic comparability trial comparing MENOPUR solution for injection in pre-filled pen, 600 IU0.96 mL and MENOPUR powder and solvent for solution for injection, 75 IU after subcutaneous administration of 300 IU in healthy women | $2.7M | 0 | 15 |
| A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults | $2.6M | 0 | 488 |
| A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events MACEs in Patients With Prostate Cancer and Cardiovascular Disease Receiving Degarelix Gonadotropin-Releasing Hormone GnRH Receptor Antagonist or Leuprolide GnRH Receptor Agonist | $1.8M | 0 | 297 |
| A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients With Prostate Cancer and Cardiovascular Disease Receiving Degarelix (Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist) | $1.3M | 0 | 429 |
| A Double-blind, Randomised, Placebo-Controlled, Phase 2b3 Adaptive Clinical Trial Investigating the Efficacy and Safety of Selepressin as Treatment for Patients With Vasopressor-dependent Septic Shock | $821,062 | 0 | 191 |
| A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection | $572,361 | 0 | 64 |
| An open-label, randomised, 2-way crossover, single dose, pharmacokinetic comparability trial comparing MENOPUR solution for injection in pre-filled pen, 600 IU/0.96 mL and MENOPUR powder and solvent for solution for injection, 75 IU after subcutaneous administration of 300 IU in healthy women | $569,399 | 0 | 4 |
| A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults with mild to Moderate Ulcerative Colitis | $507,234 | 0 | 55 |
| ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States | $314,551 | 0 | 68 |
| REBYOTA for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study | $284,922 | 0 | 91 |
| An Open-label, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults with Recurrent Clostridioides difficile Infection | $244,236 | 0 | 22 |
| A Double-blind, Randomised, Placebo-controlled, Phase 2b3 Adaptive Clinical Trial Investigating the Efficacy and Safety of Selepressin as Treatment for Patients with Vasopressor-dependent Septic Shock | $83,435 | 0 | 39 |
| A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer | $65,655 | 0 | 4 |
| A Phase 4, Multi-center, Open Label Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose | $48,866 | 0 | 5 |
| A Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC) | $17,000 | 0 | 1 |
| A Double-blind, Randomised, Placebo-Controlled, Phase 2b/3 Adaptive Clinical Trial Investigating the Efficacy and Safety of Selepressin as Treatment for Patients With Vasopressor-dependent Septic Shock | $15,005 | 0 | 6 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2019 |
|---|---|---|---|---|
| Derek Angus | Specialist | Pittsburgh, PA | $71,602 | $0 |
| Dr. Eve Feinberg, Md, MD | Reproductive Endocrinology | Chicago, IL | $69,780 | $0 |
| Roger Lewis, M.d, M.D | Emergency Medicine | Torrance, CA | $58,466 | $0 |
| Dr. Mark Williams, Md, MD | Pulmonary Disease | Indianapolis, IN | $32,809 | $0 |
| Jason Franasiak, Md, MD | Student in an Organized Health Care Education/Training Program | Chapel Hill, NC | $29,687 | $0 |
| Sahil Khanna, Mbbs, MBBS | Internal Medicine | Rochester, MN | $23,439 | $0 |
| Dr. Matt Rosenberg, M.d, M.D | Family Medicine | Jackson, MI | $20,192 | $0 |
| Thomas Easterling, Md, MD | Maternal & Fetal Medicine | Everett, WA | $16,794 | $0 |
| Dr. Jeffrey Weiss, Md, MD | Urology | Brooklyn, NY | $15,941 | $0 |
| Trinity Bivalacqua, Md Phd, MD PHD | Urology | Philadelphia, PA | $15,650 | $0 |
| Dr. Sharon Thompson, Md, Mph, MD, MPH | Obstetrics & Gynecology | Phoenix, AZ | $15,439 | $0 |
| Audra Meadows, Md, Mph, MD, MPH | Obstetrics & Gynecology | La Jolla, CA | $15,155 | $0 |
| Seth Lerner, Md, MD | Urology | Houston, TX | $14,064 | $0 |
| Vikram Narayan, Md, MD | Urology | Atlanta, GA | $13,891 | $0 |
| Dr. Bilal Chughtai, Md, MD | Urogynecology and Reconstructive Pelvic Surgery | New York, NY | $13,372 | $0 |
| Dr. Mary Hebert, M.d, M.D | Radiation Oncology | Nacogdoches, TX | $13,225 | $0 |
| Dr. Siamak Daneshmand, M.d, M.D | Urology | Los Angeles, CA | $11,943 | $0 |
| Dr. Joshua Meeks, Md, Phd, MD, PHD | Urology | Chicago, IL | $11,284 | $0 |
| Dr. Zsakeba Henderson, M.d, M.D | Obstetrics & Gynecology | Covington, GA | $9,192 | $0 |
| Dr. Subbian Karumanchi, M.d, M.D | Nephrology | Boston, MA | $8,140 | $0 |
| Prof. Pierluigi Gambetti, M.d, M.D | Research Study | Cleveland, OH | $7,926 | $0 |
| Dr. Elizabeth Mueller | Urology | Maywood, IL | $7,312 | $0 |
| Ashish Kamat, M.d, M.D | Urology | Houston, TX | $6,293 | $0 |
| Dr. Boyd Thompson, Md, MD | Pulmonary Disease | Boston, MA | $5,863 | $0 |
| Dr. Wesley Self, Md, MD | Emergency Medicine | Nashville, TN | $5,750 | $0 |
About Ferring Pharmaceuticals AS
Ferring Pharmaceuticals AS has made $12.6M in payments to 96 healthcare providers, recorded across 2,226 transactions in the CMS Open Payments database. In 2024, the company paid $1.8M. The top product by payment volume is MENOPUR ($3.3M).
Payments were distributed across 27 medical specialties. The top specialty by payment amount is Urology ($122,126 to 21 doctors).
Payment categories include: Food & Beverage ($14,349), Consulting ($425,938), Research ($12.0M), Travel & Lodging ($148,690).
Ferring Pharmaceuticals AS is associated with 3 products in the CMS Open Payments database.